Mr. Paul R. Fonteyne, MBA, has been a Director of resTORbio, Inc. since December 11, 2017. Mr. Fonteyne has been Member of the Board of Directors at Ypsomed Holding AG since July 2018. Mr. Fonteyne served as the United States Country Managing Director and President and Chief Executive Officer of Boehringer Ingelheim USA Corporation since 2011 until March 01, 2018. He serves as Chief Executive Officer and President of Boehringer Ingelheim Pharmaceuticals, Inc. Previously, Mr. Fonteyne served as Senior Corporate Vice President in Boehringer Ingelheim GmbH from 2009 to 2011. From 2003 to 2008 he served as Executive Vice President, Head of Marketing and Sales for Prescription Medicines at Boehringer-Ingelheim Pharmaceuticals, Inc. Prior to 2003, Mr. Fonteyne served in numerous leadership positions at Merck and Co. Inc, including Vice President of Sales in North Central US, Vice President of Marketing and Senior Director of Marketing. Mr. Fonteyne currently serves on the advisory board of the Brigham and Women’s Hospital Lung Center and the board of PhRMA (the leading pharmaceutical industry association). He has been Director of Gelesis, Inc. since June 5, 2018. Mr. Fonteyne received his MBA from Carnegie-Mellon University and his MS in Chemical Engineering from the Polytechnic School at the University of Brussels.